scholarly article | Q13442814 |
P50 | author | Felipe Prosper | Q37835050 |
Xabier Agirre | Q40931651 | ||
Eva Lumbreras | Q53101825 | ||
Miguel A Sanz | Q54544774 | ||
Miren Maicas | Q57157699 | ||
P2093 | author name string | Salut Brunet | |
María D Odero | |||
María J Calasanz | |||
Nerea Marcotegui | |||
Claudia Carranza | |||
Idoya Lahortiga | |||
Ana Valencia | |||
José Cervera | |||
Carmen Vicente | |||
Jorge Sierra | |||
Jesús M Hernández-Rivas | |||
Iria Vázquez | |||
Maria Gomez-Benito | |||
María T Gómez-Casares | |||
Oskar Marin-Béjar | |||
P2860 | cites work | Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family | Q24314719 |
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies | Q27824769 | ||
A bivalent chromatin structure marks key developmental genes in embryonic stem cells | Q27860977 | ||
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients | Q28209409 | ||
Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration | Q28263954 | ||
EVI1 and hematopoietic disorders: history and perspectives | Q28284034 | ||
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias | Q28301353 | ||
The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions | Q28302636 | ||
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome | Q29616819 | ||
Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. | Q33805966 | ||
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease | Q34094502 | ||
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. | Q34508425 | ||
Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors | Q36780634 | ||
Leukemogenesis of the EVI1/MEL1 gene family | Q36812700 | ||
Acute myeloid leukemia: the challenge of capturing disease variety | Q37346654 | ||
Genome‐wide DNA methylation profiling | Q37788000 | ||
EVI1 induces myelodysplastic syndrome in mice | Q39951095 | ||
BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia | Q39974408 | ||
Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends. | Q40398239 | ||
AML1 mutations induced MDS and MDS/AML in a mouse BMT model | Q42818187 | ||
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors | Q42882348 | ||
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia | Q44073895 | ||
Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. | Q44893063 | ||
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements | Q49097152 | ||
Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. | Q51956004 | ||
Prognostically useful gene-expression profiles in acute myeloid leukemia. | Q51999490 | ||
Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. | Q53361854 | ||
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. | Q54546717 | ||
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia | Q71841108 | ||
Mapping of leukaemia-associated breakpoints in chromosome band 3q21 using a newly established PAC contig | Q74260823 | ||
Diagnosis and prognosis in acute myeloid leukemia--the art of distinction | Q81197668 | ||
Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells | Q83058254 | ||
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities | Q83822325 | ||
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia | Q84596053 | ||
P433 | issue | 10 | |
P921 | main subject | acute myeloid leukemia | Q264118 |
P304 | page(s) | 1448-1456 | |
P577 | publication date | 2011-07-12 | |
P1433 | published in | Haematologica | Q5638209 |
P1476 | title | Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia | |
P478 | volume | 96 |
Q38882990 | A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells. |
Q35565945 | A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells |
Q42361215 | DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome. |
Q34606698 | EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells |
Q38314944 | EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis |
Q42979885 | EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. |
Q38299701 | EVI1 promotes tumor growth via transcriptional repression of MS4A3. |
Q55714578 | Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGFβ/EMT signaling pathway. |
Q37965026 | Epigenetic regulation of miRNA genes in acute leukemia. |
Q35726371 | Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update |
Q39332914 | Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. |
Q34516815 | High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia |
Q33412515 | Myeloid neoplasm with t(3;8)(q26;q24): report of six cases and review of the literature |
Q38166375 | Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players |
Q34849602 | Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. |
Q39305389 | Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas |
Q89651160 | The conserved and divergent roles of Prdm3 and Prdm16 in zebrafish and mouse craniofacial development |
Q41930387 | The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid |
Q52680326 | The role of zinc and its compounds in leukemia. |
Q84782684 | Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases |
Q60306602 | miR-1 inhibits the proliferation of breast cancer stem cells by targeting EVI-1 |
Search more.